ロード中...
Alemtuzumab Therapy for Multiple Sclerosis
Alemtuzumab is a humanized monoclonal antibody that is administered daily for 5 days, and then no further therapy is required for 12 months. It causes rapid and prolonged lymphocyte depletion; the consequent homeostatic reconstitution leads to a radically reformed lymphocyte pool with a relative inc...
保存先:
| 第一著者: | |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer-Verlag
2012
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3557360/ https://ncbi.nlm.nih.gov/pubmed/23184314 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13311-012-0159-0 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|